Samsung Biologics Launches All‑Cash Tender Offer for PolyPeptide Group AG

Samsung Biologics Co., Ltd., a leading contract‑development and manufacturing organization in the life‑sciences sector, announced on 20 July 2026 that it will acquire 100 % of the fully diluted share capital of PolyPeptide Group AG (SIX: PPGN) through an all‑cash public tender offer. The offer values PolyPeptide at CHF 1.46 billion, with a per‑share price of CHF 44.31, representing a 40 % premium to the last closing price of CHF 31.65 on 10 April 2026.

Offer Terms and Financial Impact

  • All‑cash offer: Samsung Biologics will pay the full purchase price in cash.
  • Premium: The CHF 44.31 per‑share offer reflects a 40 % premium over PolyPeptide’s April 10 closing price, underscoring the strategic value assigned to PolyPeptide’s peptide‑manufacturing capabilities.
  • Fairness opinion: IFBC AG has issued an independent fairness opinion supporting the offer’s price, reinforcing the financial soundness of the transaction.
  • Board endorsement: PolyPeptide’s board of directors has unanimously recommended that shareholders accept the tender, citing the transaction’s strategic and financial benefits.
  • Largest shareholder backing: PolyPeptide’s principal shareholder, holding approximately 55.65 % of outstanding shares (excluding treasury shares), has provided an irrevocable tender undertaking, indicating strong support for the deal.

Strategic Rationale

Samsung Biologics aims to accelerate its multi‑modality strategy by adding PolyPeptide’s specialized peptide expertise and its global multi‑site manufacturing network. The acquisition is expected to:

  1. Expand global manufacturing coverage – extending Samsung Biologics’ footprint across the United States, Europe, and India.
  2. Strengthen peptide‑based active pharmaceutical ingredient (API) capabilities – complementing Samsung Biologics’ existing services in cell culture, purification, and aseptic fill‑and‑finish.
  3. Accelerate long‑term growth – providing a platform for new product development and broader client service offerings within the life‑sciences tools and services sector.

Preliminary First‑Half Results

PolyPeptide announced that it has successfully closed its first‑half of 2026, delivering preliminary results that demonstrate continued operational performance. The announcement of the tender offer coincides with these results, providing investors with a comprehensive view of the company’s recent financial health.

Market Context

Samsung Biologics, listed on the Korea Exchange Stock Market, reported a closing price of KRW 1,345,000 on 19 July 2026. The company’s market capitalization stands at KRW 64.62 trillion, with a price‑to‑earnings ratio of 52.54. The acquisition aligns with Samsung Biologics’ strategy of expanding its contract‑manufacturing services, which already include biosimilar production (e.g., Enbrel, Remicade, Humira, Herceptin) and various upstream, downstream, and analytical technologies.

The information presented herein is based on publicly available press releases and company statements dated 19–20 July 2026. No additional analysis or speculation has been included.